Services on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Acta médica Grupo Ángeles
Print version ISSN 1870-7203
Abstract
HURTADO MONROY, Rafael et al. Imatinib mesylate as first-line treatment in patients with chronic myeloid leukemia Philadelphia + (CML-Ph+) in accelerated phase (AF), compared to chronic phase (CF). A long-term retrospective study. Acta méd. Grupo Ángeles [online]. 2018, vol.16, n.3, pp.204-208. ISSN 1870-7203.
Introduction:
The accelerated phase is a condition of progression of the CML. Our first line of treatment is imatinib mesylate (IM); however, there is no information on long-term outcomes in AP.
Material and methods:
We conducted a retrospective comparative study of patients with CML Ph+. Patients with CP received IM 400 mg/day and patients with AP 600 mg/day, both were followed with cytogenetic studies with fluorescence in situ hybridization (FISH) (minimum 200 nuclei analyzed) every three months.
Results:
The median time for the complete cytogenetic response (CCyR) was eight months in CP and 12 months in AP. The length of this response in CP was 73 months in 100% of patients and 30 months in 42.9% of AP. The median survival (follow-up of 120 months) was 70 months in AP and 150 months in CP (p < 0.0001). The median long-term free-disease and overall survival was 73 months in CP and 30 months in AP.
Conclusions:
The AP has lower CCyR and survival, which suggests the need to change the initial treatment.
Keywords : Chronic myeloid leukemia; imatinib; accelerated phase.
